Economic Atlas
Companies/Harvard Bioscience, Inc.
Company profile

Harvard Bioscience, Inc.

NASDAQ: HBIO · Healthcare · Medical - Instruments & Supplies
PublicHQ Holliston, MACIK 0001123494Reports USD
#363 of 1,418 Healthcare companies by revenue33rd-percentile growth
EA Score
58C
Revenue TTM
$85.5M
Rev growth YoY (TTM)
-6.4%
Net income (FY)
-$56.7M
Employees
328
as of 2026-08-20
Market cap
$31.9M
as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$86.5M$86.5M2025
Net income-$56.7M-$56.7M2025
Operating income-$48.6M-$48.6M2025
Total assets$80.1M$80.1M2025
Liabilities$66.3M$66.3M2025
Equity$13.7M$13.7M2025

Revenue trend

FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
Instruments, Equipment, Software, and Accessories90%
Service, Maintenance, and Warranty Contracts10%
By geography
UNITED STATES45%
EMEA31%
CHINA13%
Asia, Other8%
Americas, Other4%
The read

What is Harvard Bioscience, Inc.’s revenue?

Harvard Bioscience, Inc. booked $86.5M in FY2025 revenue, contracting 8.1% year over year — slower than 67% of Healthcare companies we track, at a -65.5% net margin.

Peers · Healthcare
Biodesix, Inc.57CCytokinetics, Incorporated59CFluent Corp.45D4Front Ventures Corp.——Standard BioTools Inc.61CDelcath Systems, Inc.72B
Key facts
CEOJohn D. Duke
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersHolliston, MA
ExchangeNASDAQ: HBIO
Employees328
IPO date2001-03-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.